Heart transplants from donors positive for hepatitis C
(JAMA Network) Researchers at Vanderbilt University Medical Center in Nashville, Tenn., report in this case series on 80 patients who had heart transplants using hearts from donors positive for hepatitis C.
The advent of therapies for successful treatment of Hepatitis C Virus (HCV) has allowed the heart and lung transplant community to re-explore the use of HCV positive donors for organ transplantation, with a benefit for many terminally ill patients. The consensus statements provided herein represent the current state of knowledge and expertise in this area, which we expect will continue to rapidly evolve over the next few years.
THE UNITED Network for Organ Sharing (UNOS) adopted the label “high risk” from the Public Health Service (PHS) in 2004 in order to improve organ safety by reducing disease transmission. This has resulted in nonutilization of organs from patients who are otherwise healthy but deemed high risk because of social behaviors or illicit drug use. Organ availabili ty remains the limiting factor to organ transplantation, and the number of patients awaiting transplantation is outpacing the number of transplantations being performed.
Title: Heart Transplants From Donors With Hepatitis C May Be Safe: StudyCategory: Health NewsCreated: 1/13/2020 12:00:00 AMLast Editorial Review: 1/14/2020 12:00:00 AM
WEDNESDAY, Jan. 8, 2020 -- Adult heart transplants from hepatitis C virus-positive (HCV+) donors appear safe, with no increased risk for adverse effects on one-year survival, according to a study published online Jan. 8 in the Journal of the...
(American Heart Association) One-year survival was 90% for adults with severe heart failure who received a heart transplant from a donor with hepatitis C, which was nearly identical to those who received a heart from donors who did not have hepatitis C (91%). Rates of organ rejection, stroke and kidney dialysis were similar between the two groups. More research is needed to assess longer-term results, however, increased use of hearts from donors with hepatitis C could help overcome the national shortage of donor organs.
An unprecedented number of heart transplants were performed in the United States during 2016,1 yet 15% of patients on the waitlist either died or became too sick for transplant.2 Wait times remain unacceptably high for heart transplant candidates. As a result, there has been growing interest in the development of innovative strategies to mitigate the donor organ shortage. During the past decade, the opioid epidemic in the United States has led to a dramatic increase in the number of organ donors who died as a result of drug intoxication.
National data demonstrate that increasing opportunities exist for organ donation among hepatitis C virus (HCV) infected individuals.
National data demonstrate that increasing opportunities exist for organ donation among hepatitis C virus (HCV) –infected individuals.
In conclusion, our data show how oncogenic and tumor-suppressive drivers of cellular senescence act to regulate surveillance processes that can be circumvented to enable SnCs to elude immune recognition but can be reversed by cell surface-targeted interventions to purge the SnCs that persist in vitro and in patients. Since eliminating SnCs can prevent tumor progression, delay the onset of degenerative diseases, and restore fitness; since NKG2D-Ls are not widely expressed in healthy human tissues and NKG2D-L shedding is an evasion mechanism also employed by tumor cells; and since increasing numbers of B cells express NKG2D ...
Previous studies suggest that direct-acting anti-virals (DAAs) for the treatment of hepatitis C virus (HCV) infection permits the transplantation of HCV-viremic donor organs in uninfected recipients. This opportunity may expand the donor pool. We assessed the impact of using HCV nucleic acid test –positive (NAT+) donor hearts on heart transplant (HTx) waitlist time and transplant rate.